Case 1: Heavy Menstrual Bleeding in a Hormone-Averse Woman

Program Description:

Heavy menstrual bleeding (HMB) is common, distressing, and treatable via a variety of surgical and pharmacologic methods, each with benefits and drawbacks that make them more or less appropriate for an individual woman. This case study addresses HMB management in a woman who is averse to hormonal medications and has other strong preferences that affect treatment decisions.

This is Case 1 of three cases. To earn additional credit, please read:
Case 2: Heavy Menstrual Bleeding in a Woman with Fibroids, Anemia, and Plans for Future Pregnancy
Case 3: Heavy Menstrual Bleeding in an Obese Woman

Activity Objectives:

After completing this activity, clinicians should be better able to:

• Explain how to diagnose HMB.


• Categorize treatments for HMB according to their effect on fertility or patients’ needs.

Faculty:

Author
Andrew M. Kaunitz, MD
Professor and Associate Chairman
Department of Obstetrics and Gynecology
The University of Florida College of Medicine-Jacksonville

Faculty/Reviewers
Anne Moore, APN, WHNP/ANP-BC
Professor of Nursing
Vanderbilt University
Nashville, TN

Lee P. Shulman, MD
Anna Ross Lapham Professor in Obstetrics and Gynecology
Chief, Division of Clinical Genetics
Feinberg School of Medicine of Northwestern University
Adjunct Professor of Medicinal Chemistry and Pharmacognosy
University of Illinois at Chicago College of Pharmacy

Disclosures:

Andrew M. Kaunitz, MD, has received research grants from Agile Therapeutics, Bayer HealthCare Pharmaceuticals, Noven Pharmaceuticals, Inc., and Teva Pharmaceuticals. He is also a consultant for Bayer HealthCare Pharmaceuticals, Merck & Co., Inc., Noven Pharmaceuticals, Inc., and Teva Pharmaceuticals. Dr. Kaunitz is also a stockholder in Becton, Dickinson and Company and sanofi-aventis.

Anne Moore, APN, WHNP/ANP-BC, is on the speakers’ bureau of Bayer HealthCare Pharmaceuticals.

Lee P. Shulman, MD, is on the speaker’s bureau of Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Merck & Co., Inc., Teva Pharmaceuticals, and Sequenom, Inc. He has received research grants from Bayer HealthCare Pharmaceuticals. Dr. Shulman is a consultant for Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Genzyme Corporation, Sequenom, Inc, and Teva Pharmaceuticals.

Disclosure of Conflicts of Interest
To provide the highest quality of CME programming and in compliance with the ACCME Standards for Commercial Support, Omnia Education requires that all faculty and planning committee members disclose relevant financial relationships with any commercial interest that produces, markets or distributes health care goods or services. Omnia Education assesses conflict of interest with its faculty, planners, authors and reviewers of its CME activities. The content is thoroughly reviewed and any conflicts of interest are resolved by independent reviewers to ensure fair balance, scientific objectivity of studies utilized in the activity and unbiased patient care recommendations. Omnia Education is committed to providing its learners with high quality, unbiased and state-of-the-art education.

Accreditor
This program is sponsored by Omnia Education.

Omnia Education is dedicated to providing the medical community with credible, evidence-based education on new and emerging discoveries within women’s healthcare. Our continuing medical education activities provide the latest information for addressing the unique needs of the female patient.

When participating in an Omnia Education activity, you can expect active learning processes that include strategies on the application of knowledge into your practice and ancillary tools that supplement the educational process. Our goal is to provide you with relevant education that meets identified needs so that results are measurable and sustained therefore resulting in improved patient care.

If you have any questions relating to the accreditation of this activity, please contact
Omnia Education
800.889.4944
www.omniaeducation.com
info@omniaeducation.com

Grantor
This program is supported by an educational grant from Ferring Pharmaceuticals.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Omnia Education and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Omnia Education and Haymarket Medical Education or the supporter, Ferring Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

OMNIA EDUCATION PRIVACY POLICY
Omnia Education understands how important the privacy of personal information is to our participants. Omnia Education is committed to honoring your privacy and to offering special protections for any information you choose to share with us. The information you are reading describes what information we may collect about you, how it may be used, and what precautions we take against unauthorized access or use of your information.

Omnia Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your non-public personal information. When you provide us with personally identifiable information, we will take appropriate steps to protect the information you share with us. In this regard, our policy is that we do not give, sell or otherwise transfer your personally identifiable information to anyone outside the Omnia Education organization or selected Omnia Education partners unless we first disclose to you at the time of collection that your personal information may be provided to third parties. However, there are certain limited instances where we may disclose or transfer personally identifiable information. For example, we may provide such information to appropriate authorities if we believe in good faith that the law requires it or to protect the legal rights or property of Omnia Education. Additionally, as we continue to develop our business, we may buy or sell business assets. In such transactions, customer information is generally one of the transferred business assets. However, we are not in the business of selling customer information to others, and aside from certain exceptional circumstances, we will take appropriate measures to ensure the protection of the information you provide to us.

Instructions:

To obtain credit, a score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.

SYSTEM REQUIREMENTS:

WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.

MACINTOSH^® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20 MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands of Colors”; Macromedia Flash Player 6 or higher.